Epidermal growth factor receptor inhibitors are used to treat advanced lung cancer patients for almost a decade. Current knowledge on their role in the first or subsequent lines of therapy serves as a model for other targeted therapies in development. Several molecular predictors of outcomes were successfully identified in preclinical and clinical studies. Evaluation of EGFR-activating mutations is currently used to define biologically distinct patient subsets with important consequences for prognosis and therapy. Ongoing translational and clinical research exploring EGFR inhibition in lung cancer focuses on better understanding of biology of EGFR-driven disease, efficacy of novel irreversible EGFR inhibitors and monoclonal antibodies, efficacy of combination strategies, and attempts to move EGFR inhibitors into therapy portfolio for early-stage disease.

译文

表皮生长因子受体抑制剂被用于治疗晚期肺癌患者近十年。目前关于它们在治疗的第一线或后续线中的作用的知识可作为开发中其他靶向疗法的模型。在临床前和临床研究中成功鉴定了几种预后的分子预测因子。 EGFR激活突变的评估目前用于定义生物学上不同的患者亚组,对预后和治疗产生重要影响。正在进行的针对肺癌中EGFR抑制的转化和临床研究致力于更好地理解EGFR驱动疾病的生物学特性,新型不可逆EGFR抑制剂和单克隆抗体的功效,联合策略的功效以及尝试将EGFR抑制剂纳入早期治疗方案中分期疾病。

+1
+2
100研值 100研值 ¥99课程
检索文献一次
下载文献一次

去下载>

成功解锁2个技能,为你点赞

《SCI写作十大必备语法》
解决你的SCI语法难题!

技能熟练度+1

视频课《玩转文献检索》
让你成为检索达人!

恭喜完成新手挑战

手机微信扫一扫,添加好友领取

免费领《Endnote文献管理工具+教程》

微信扫码, 免费领取

手机登录

获取验证码
登录